Aurobindo Pharma's stock rose after its subsidiary got approval for a cancer drug. CuraTeQ Biologics received the UK's MHRA approval for Bevgolva. This biosimilar treats various cancers. The company also saw recent USFDA observations and EMA approval for another drug. Aurobindo's Q2 profits increased. Revenue also grew compared to last year.
